Algee

Jul 11, 2022

Burden of PSMA-expressing prostate cancer before and after treatment with two cycles of Lu-177 PSMA-617. (A and B) Reduction in overall disease burden is evident after treatment. Avidity of patient’s primary prostate tumor and his osseous metastasis shown before (C) and after (D) treatment.

Case report: Pluvicto as a first-line treatment in late-stage prostate cancer

September 26, 2025

New brain MRI imaging technique could help identify Alzheimer's

September 26, 2025

Digital Innovations Shaping the Future of Radiology

Digital Innovations Shaping the Future of Radiology

September 24, 2025

3D DEXA shows value in patients with prostate cancer

September 25, 2025

Case report: Pluvicto as a first-line treatment in late-stage prostate cancer

Since 1996, the patient continually declined androgen deprivation therapy, chemotherapy, and local therapy to the prostate gland.

September 26, 2025

Burden of PSMA-expressing prostate cancer before and after treatment with two cycles of Lu-177 PSMA-617. (A and B) Reduction in overall disease burden is evident after treatment. Avidity of patient’s primary prostate tumor and his osseous metastasis shown before (C) and after (D) treatment.

New brain MRI imaging technique could help identify Alzheimer's

By Kate Madden Yee

Researchers used 7-tesla MRI to demonstrate how microvessel pulses in the brain's deep white matter increase with age.

September 26, 2025

Scholarly activity low among residency program directors

By Amerigo Allegretto

Study results point toward program directors focusing on administrative responsibilities rather than scholarly activity.

September 26, 2025

Research Highlighter Res

3D DEXA shows value in patients with prostate cancer

3D DEXA may be a practical and valuable tool for detecting structural bone changes in prostate cancer patients.

September 25, 2025

Smith-Bindman unpacks NEJM pediatric CT study

By Kate Madden Yee

In a video interview, the researcher acknowledged CT's importance to patient care but advocated for its appropriate use.

September 25, 2025

Rebecca Smith-Bindman, MD

Women who skip first mammogram more likely to die of breast cancer

By Amerigo Allegretto

Women who do not participate in their first breast cancer screening are 40% more likely to die later from the disease.

September 24, 2025

Mammography Breast Ipad Patient 400

Study finds AI not cost-effective for breast cancer screening

By Amerigo Allegretto

AI is not cost-effective for breast cancer screening, even with reductions in mortality, false-positive cases, and false-negative cases, according to new research.

September 24, 2025

Breast Tomosynthesis Digital 400 (1)

ACS: Cancer survival rates are lower in rural areas

By Kate Madden Yee

The research also reported lower cancer survival rates for Blacks compared to whites, underscoring "disparities in receipt of care."

September 24, 2025

Save power, curb carbon by switching off surplus CT scanners

By Kate Madden Yee

A new study's findings suggest a relatively easy way to "go green" in the radiology suite.

September 23, 2025

Planet Sustainability

Radiologists deem AI x-ray reports clinically acceptable

There was no evidence of a difference in acceptability between AI- and radiologist-generated reports under a standard criterion.

September 23, 2025

ACR CEO talks imaging’s role in spending bill

By Amerigo Allegretto

Dana Smetherman, MD, CEO of the ACR, spoke with AuntMinnie.com about appropriations bills and how imaging may be affected.

September 23, 2025

American Flag Waving 400 (1)

Adding MBI to DBT finds more breast cancers

By Amerigo Allegretto

Adding molecular breast imaging (MBI) to DBT screening leads to more invasive cancers detected in women with dense breasts.

September 23, 2025

Images in a 62-year-old woman who presented for screening. (A) Image from DBT screening (the synthesized 2D mediolateral oblique view of the left breast is shown) at year on was interpreted as negative and showing heterogeneously dense breast. (B) Image from molecular breast imaging screening (mediolateral oblique view) at year one reveals a 0.9-cm non-mass focal area of uptake in the left breast (arrow). (C) Targeted ultrasound scan (transverse image) shows a suspicious mass in the 3-o’clock position of the left breast, 4 cm from the nipple. Ultrasound-guided core biopsy and lumpectomy revealed a 0.9-cm grade 2 invasive ductal carcinoma, an estrogen receptor–negative, progesterone receptor–negative, human epidermal growth factor receptor 2–negative lesion, with two sentinel nodes negative (N0).

Page 1 of 173